These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9501472)

  • 1. Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan.
    Nagase H; Hayakawa J; Kawamura K; Kawai K; Takezawa Y; Matsuura H; Tajima C; Endo T
    Chem Pharm Bull (Tokyo); 1998 Feb; 46(2):366-9. PubMed ID: 9501472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (-)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice.
    Takasaki I; Suzuki T; Sasaki A; Nakao K; Hirakata M; Okano K; Tanaka T; Nagase H; Shiraki K; Nojima H; Kuraishi Y
    J Pharmacol Exp Ther; 2004 Apr; 309(1):36-41. PubMed ID: 14711930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist.
    Endoh T; Matsuura H; Tajima A; Izumimoto N; Tajima C; Suzuki T; Saitoh A; Suzuki T; Narita M; Tseng L; Nagase H
    Life Sci; 1999; 65(16):1685-94. PubMed ID: 10573186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and structure-activity relationship of novel opioid kappa-agonists.
    Kawai K; Hayakawa J; Miyamoto T; Imamura Y; Yamane S; Wakita H; Fujii H; Kawamura K; Matsuura H; Izumimoto N; Kobayashi R; Endo T; Nagase H
    Bioorg Med Chem; 2008 Oct; 16(20):9188-201. PubMed ID: 18829333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys.
    Endoh T; Tajima A; Izumimoto N; Suzuki T; Saitoh A; Suzuki T; Narita M; Kamei J; Tseng LF; Mizoguchi H; Nagase H
    Jpn J Pharmacol; 2001 Mar; 85(3):282-90. PubMed ID: 11325021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
    Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
    Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the antinociceptive effects of TRK-820 in the rat.
    Endoh T; Tajima A; Suzuki T; Kamei J; Narita M; Tseng L; Nagase H
    Eur J Pharmacol; 2000 Jan; 387(2):133-40. PubMed ID: 10650153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syntheses of 10-oxo, 10 alpha-hydroxy, and 10 beta-hydroxy derivatives of a potent kappa-opioid receptor agonist, TRK-820.
    Horikiri H; Hirano N; Tanaka Y; Oishi J; Hatakeyama H; Kawamura K; Nagase H
    Chem Pharm Bull (Tokyo); 2004 Jun; 52(6):664-9. PubMed ID: 15187385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Peripheral κ-Opioid Receptor Agonists as Novel Analgesics.
    Suzuki S; Sugawara Y; Inada H; Tsuji R; Inoue A; Tanimura R; Shimozono R; Konno M; Ohyama T; Higashi E; Sakai C; Kawai K
    Chem Pharm Bull (Tokyo); 2017; 65(11):1085-1088. PubMed ID: 29093296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice.
    Tsuji M; Yamazaki M; Takeda H; Matsumiya T; Nagase H; Tseng LF; Narita M; Suzuki T
    Eur J Pharmacol; 2000 Apr; 394(1):91-5. PubMed ID: 10771039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.
    Wang Y; Tang K; Inan S; Siebert D; Holzgrabe U; Lee DY; Huang P; Li JG; Cowan A; Liu-Chen LY
    J Pharmacol Exp Ther; 2005 Jan; 312(1):220-30. PubMed ID: 15383632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions.
    Suzuki T; Izumimoto N; Takezawa Y; Fujimura M; Togashi Y; Nagase H; Tanaka T; Endoh T
    Brain Res; 2004 Jan; 995(2):167-75. PubMed ID: 14672806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of highly selective κ-opioid receptor agonists: 10α-Hydroxy TRK-820 derivatives.
    Suzuki S; Sugawara Y; Tsuji R; Tanimura R; Kaneko C; Yuzawa N; Yagi M; Kawai K
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3920-3924. PubMed ID: 28688957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats.
    Mori T; Nomura M; Nagase H; Narita M; Suzuki T
    Psychopharmacology (Berl); 2002 Apr; 161(1):17-22. PubMed ID: 11967626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates.
    Ko MC; Husbands SM
    J Pharmacol Exp Ther; 2009 Jan; 328(1):193-200. PubMed ID: 18842704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence.
    Hasebe K; Kawai K; Suzuki T; Kawamura K; Tanaka T; Narita M; Nagase H; Suzuki T
    Ann N Y Acad Sci; 2004 Oct; 1025():404-13. PubMed ID: 15542743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
    Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
    Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system.
    Umeuchi H; Togashi Y; Honda T; Nakao K; Okano K; Tanaka T; Nagase H
    Eur J Pharmacol; 2003 Sep; 477(1):29-35. PubMed ID: 14512095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.